<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04508426</url>
  </required_header>
  <id_info>
    <org_study_id>AR882-103</org_study_id>
    <nct_id>NCT04508426</nct_id>
  </id_info>
  <brief_title>Single-dose AME Study With [14C]AR882 in Healthy Male Subjects</brief_title>
  <official_title>A Phase 1, Absorption, Metabolism, and Excretion Study of [14C]AR882 Orally Administered to Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arthrosi Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celerion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Arthrosi Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-dose, absorption, metabolism, excretion, and mass balance study&#xD;
      following a single dose of [14C]AR882 in healthy adult male subjects. Whole blood, plasma,&#xD;
      urine, and fecal samples will be analyzed for at least 144 hours following the single dose of&#xD;
      AR882 to measure total radioactivity and plasma drug concentrations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 16, 2020</start_date>
  <completion_date type="Actual">August 12, 2020</completion_date>
  <primary_completion_date type="Actual">August 12, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total radioactivity (TRA) in urine</measure>
    <time_frame>Days 1-14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>TRA in feces</measure>
    <time_frame>Days 1-14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>TRA concentration equivalents in plasma</measure>
    <time_frame>Days 1-14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>TRA concentration equivalents in whole blood</measure>
    <time_frame>Days 1-14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) for plasma [14C]-AR882</measure>
    <time_frame>7 Days</time_frame>
    <description>Profile from plasma in terms of AUC following a single dose of [14C]-AR882</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum plasma concentration (Tmax) for [14C]-AR882</measure>
    <time_frame>7 Days</time_frame>
    <description>Profile from plasma in terms of Tmax following a single dose of [14C]-AR882</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) for [14C]-AR882</measure>
    <time_frame>7 Days</time_frame>
    <description>Profile from plasma in terms of Cmax following a single dose of [14C]-AR882</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal half-life (t1/2) for [14C]-AR882</measure>
    <time_frame>7 Days</time_frame>
    <description>Profile from plasma in terms of t1/2 following a single dose of [14C]-AR882</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events, changes in laboratory, electrocardiogram, and vital signs [14C]-AR882</measure>
    <time_frame>Days 1-14</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Mass Balance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]AR882</intervention_name>
    <description>Single dose of [14C]AR882</description>
    <arm_group_label>Mass Balance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body weight no less than 50 kg and body mass index (BMI) within the range of ≥ 18 and&#xD;
             ≤ 33 kg/m2&#xD;
&#xD;
          -  Must have a minimum of 1 bowel movement every 2 days&#xD;
&#xD;
          -  Medically healthy with no clinically significant medical history, physical&#xD;
             examination, laboratory profiles, vital signs or ECGs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inadequate venous access or unsuitable veins for repeated venipuncture&#xD;
&#xD;
          -  Positive serology to HIV (HIV1 and HIV2) and/or Hepatitis C antibodies, and/or&#xD;
             Hepatitis B&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Celerion, Inc.</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 6, 2020</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2020</study_first_posted>
  <last_update_submitted>November 12, 2020</last_update_submitted>
  <last_update_submitted_qc>November 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

